Sava
A next-generation wearable that tracks a broad range of biomarkers in real time.
brand facts
- Continuous glucose monitors (CGMs) are rapidly gaining popularity. Initially developed for the diabetic market, they are now increasingly used by everyday consumers as wearable health technology becomes more mainstream (for example, the Zoe patch). The market is currently dominated by DexCom and Abbott, whose devices are often expensive and uncomfortable.
- Sava is tackling this problem by creating CGMs that are more affordable and less painful, with the potential to track additional biomarkers such as alcohol and cortisol, providing users with real-time insights into their health.
- The company was founded in 2019 by Renato Circe and Rafaël Michali, who met while studying Biomedical Engineering at Imperial College.
Brand categories
- venture capital
- health-fitness-beauty
- UK & international
- current
Our journey with Sava
True invested in Sava’s Series A in 2024, alongside Balderton Capital and Norrsken, and we are excited to support the team as they expand access to real-time health monitoring for everyday consumers.